

CODE/NAME & ADDRESS: C000138355

ACROFEMI HEALTHCARE LTD (MEDIWHEEL)
F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHÍ

NEW DELHI 110030 8800465156 ACCESSION NO : **0290WD005364**

PATIENT ID : ALKAF291177290

CHIENT BATIENT ID:

AGE/SEX :45 Years Female

DRAWN :

RECEIVED : 22/04/2023 11:11:34 REPORTED : 24/04/2023 16:43:55

Test Report Status Final Results Biological Reference Interval Units

MEDI WHEEL FULL BODY HEALTH CHECKUP ABOVE 40FEMALE

XRAY-CHEST

»» BOTH THE LUNG FIELDS ARE CLEAR

»» BOTH THE COSTOPHRENIC AND CARIOPHRENIC ANGELS ARE CLEAR

»»
BOTH THE HILA ARE NORMAL

»» CARDIAC AND AORTIC SHADOWS APPEAR NORMAL»» BOTH THE DOMES OF THE DIAPHRAM ARE NORMAL

»» VISUALIZED BONY THORAX IS NORMAL

IMPRESSION

NO ABNORMALITY DETECTED

Dr G.S. Saluja, (MBBS,DMRD) (Consultant Radiologist)

TMT OR ECHO

TMT OR ECHO NEGATIVE

ECG

ECG

SINUS RHYTHM.

NORMAL ECG.

MAMOGRAPHY (BOTH BREASTS)

MAMOGRAPHY BOTH BREASTS

NORMAL

MEDICAL HISTORY

RELEVANT PRESENT HISTORY

NOT SIGNIFICANT

RELEVANT PAST HISTORY

DM-2YEARS

S/H/O :- LSCS - 2005 AND 2009

RELEVANT PERSONAL HISTORY

RELEVANT FAMILY HISTORY

OCCUPATIONAL HISTORY

HISTORY OF MEDICATIONS

NOT SIGNIFICANT

NOT SIGNIFICANT

ANTHROPOMETRIC DATA & BMI

HEIGHT IN METERS 1.51 mts

Dr.Arpita Pasari, MD Consultant Pathologist



Page 1 Of 21

View Details

View Report





PATIENT NAME : ALKA SHRIVASTAVA REF. DOCTOR : DR. ACROFEMI HEALTHCARE LTD

(MEDIWHEEL)

CODE/NAME & ADDRESS : C000138355

ACROFEMI HEALTHCARE LTD (MEDIWHEEL)

F-703 LADO SARAI MEHRAULISQUITH WEST

F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030 8800465156 ACCESSION NO : 0290WD005364

PATIENT ID : ALKAF291177290

CHIENT BATIENT ID:

AGE/SEX :45 Years Female

DRAWN :

RECEIVED : 22/04/2023 11:11:34 REPORTED : 24/04/2023 16:43:55

Test Report Status	Final	Results	Biological Reference Interval	Units

WEIGHT IN KGS. 64 Kgs

BMI 28 BMI & Weight Status as follows/sqmts

Below 18.5: Underweight 18.5 - 24.9: Normal 25.0 - 29.9: Overweight 30.0 and Above: Obese

GENERAL EXAMINATION

MENTAL / EMOTIONAL STATE NORMAL
PHYSICAL ATTITUDE NORMAL
GENERAL APPEARANCE / NUTRITIONAL OVERWEIGHT

STATUS

BUILT / SKELETAL FRAMEWORK

FACIAL APPEARANCE

SKIN

UPPER LIMB

LOWER LIMB

NORMAL

NORMAL

NORMAL

NORMAL

NECK LYMPHATICS / SALIVARY GLANDS NOT ENLARGED OR TENDER

THYROID GLAND NOT ENLARGED CAROTID PULSATION NORMAL

CAROTID PULSATION NORMAL TEMPERATURE AFEBRILE

PULSE 72/MIN, REGULAR, ALL PERIPHERAL PULSES WELL FELT, NO CAROTID

BRUIT

RESPIRATORY RATE NORMAL

CARDIOVASCULAR SYSTEM

BP 120/80 MM HG mm/Hg

(SUPINE) NORMAL NORMAL

PERICARDIUM NORMAL
APEX BEAT NORMAL
HEART SOUNDS NORMAL
MURMURS ABSENT

RESPIRATORY SYSTEM

SIZE AND SHAPE OF CHEST NORMAL MOVEMENTS OF CHEST SYMMETRICAL

Dr.Arpita Pasari, MD Consultant Pathologist Page 2 Of 21





View Details

View Repor





PATIENT ID

CODE/NAME & ADDRESS : C000138355 ACROFEMI HEALTHCARE LTD (MEDIWHEEL)

F-703, LADO SARAI, MEHRAULISOUTH WEST **DELHI**

NEW DELHI 110030 8800465156

ACCESSION NO: 0290WD005364

: ALKAF291177290 CHIENT BATIENT ID:

:45 Years AGE/SEX Female

DRAWN

RECEIVED: 22/04/2023 11:11:34 REPORTED :24/04/2023 16:43:55

Results Biological Reference Interval **Test Report Status** Units **Final**

BREATH SOUNDS INTENSITY **NORMAL**

VESICULAR (NORMAL) BREATH SOUNDS QUALITY

ABSENT ADDED SOUNDS

PER ABDOMEN

APPEARANCE NORMAL VENOUS PROMINENCE **ABSENT**

LIVER NOT PALPABLE SPLEEN NOT PALPABLE ABSENT HERNIA

CENTRAL NERVOUS SYSTEM

HIGHER FUNCTIONS **NORMAL** CRANIAL NERVES **NORMAL** CEREBELLAR FUNCTIONS **NORMAL NORMAL** SENSORY SYSTEM **NORMAL** MOTOR SYSTEM **NORMAL REFLEXES**

MUSCULOSKELETAL SYSTEM

SPINE NORMAL **NORMAL** JOINTS

BASIC EYE EXAMINATION

NORMAL CONJUNCTIVA **EYELIDS** NORMAL EYE MOVEMENTS NORMAL **CORNEA NORMAL**

DISTANT VISION RIGHT EYE WITHOUT 6/6, WITHIN NORMAL LIMIT

GLASSES

DISTANT VISION LEFT EYE WITHOUT 6/6, WITHIN NORMAL LIMIT

GLASSES

NEAR VISION RIGHT EYE WITHOUT GLASSES N6, WITHIN NORMAL LIMIT NEAR VISION LEFT EYE WITHOUT GLASSES N6, WITHIN NORMAL LIMIT

NORMAL COLOUR VISION

BASIC ENT EXAMINATION

EXTERNAL EAR CANAL **NORMAL**

Dr. Arpita Pasari, MD

Consultant Pathologist





Page 3 Of 21





CODE/NAME & ADDRESS: C000138355 ACCESSION
ACROFEMI HEALTHCARE LTD (MEDIWHEEL) PATIENT ID

F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030 8800465156 ACCESSION NO: 0290WD005364

PATIENT ID : ALKAF291177290

CHIENT BATTENT ID:

AGE/SEX :45 Years Female

DRAWN :

RECEIVED : 22/04/2023 11:11:34 REPORTED : 24/04/2023 16:43:55

Test Report Status Final Results Biological Reference Interval Units

TYMPANIC MEMBRANE NORMAL

NOSE NO ABNORMALITY DETECTED

SINUSES NORMAL THROAT NORMAL

TONSILS NOT ENLARGED

SUMMARY

RELEVANT HISTORY NOT SIGNIFICANT RELEVANT GP EXAMINATION FINDINGS OVERWEIGHT

REMARKS / RECOMMENDATIONS NONE

FITNESS STATUS

FITNESS STATUS FIT (WITH MEDICAL ADVICE) (AS PER REQUESTED PANEL OF TESTS)

Comments

CLINICAL FINDINGS:-

DYSLIPIDEMIA.

RAISED PPBS

OVER WEIGHT STATUS.

FITNESS STATUS :-

FITNESS STATUS: FIT (WITH MEDICAL ADVICE) (AS PER REQUESTED PANEL OF TESTS)

ADVICE: WEIGHT REDUCTION, LOW FAT& CARBOHYDRATE DIET AND REGULAR PHYSICAL EXERCISE FOR OVERWEIGHT STATUS AND DYSLIPIDEMIA.

NEED PHYSICIAN CONSULTATION FOR LIFE STYLE MODIFICATION.

Dr.Arpita Pasari, MD Consultant Pathologist



Page 4 Of 21

iew Details

View Denovi







REF. DOCTOR: DR. ACROFEMI HEALTHCARE LTD **PATIENT NAME: ALKA SHRIVASTAVA** (MEDIWHEEL)

PATIENT ID

CODE/NAME & ADDRESS : C000138355 ACROFEMI HEALTHCARE LTD (MEDIWHEEL)

F-703, LADO SARAI, MEHRAULISOUTH WEST

CHIENT BATTENT ID: DELHI **NEW DELHI 110030** 8800465156

ACCESSION NO: 0290WD005364

: ALKAF291177290

:45 Years AGE/SEX

Female

DRAWN RECEIVED: 22/04/2023 11:11:34

REPORTED :24/04/2023 16:43:55

Units **Test Report Status** Results **Final**

MEDI WHEEL FULL BODY HEALTH CHECKUP ABOVE 40FEMALE ULTRASOUND ABDOMEN

ULTRASOUND ABDOMEN NO ABNORMALITIES DETECTED

Interpretation(s)

MEDICAL

HISTORY-**** THIS REPORT CARRIES THE SIGNATURE OF OUR LABORATORY DIRECTOR. THIS IS AN INVIOLABLE FEATURE OF OUR LAB MANAGEMENT SOFTWARE. HOWEVER, ALL EXAMINATIONS AND INVESTIGATIONS HAVE BEEN CONDUCTED BY OUR PANEL OF DOCTORS.

FITNESS STATUS-Conclusion on an individual's Fitness, which is commented upon mainly for Pre employment cases, is based on multi factorial findings and does not depend on any one single parameter. The final Fitness assigned to a candidate will depend on the Physician's findings and overall judgement on a case to case basis, details of the candidate's past and personal history as well as the comprehensiveness of the diagnostic panel which has been requested for .These are then further correlated with details of the job under consideration to eventually fit the right man to the right job.

- Basis the above, SRL classifies a candidate's Fitness Status into one of the following categories:

 Fit (As per requested panel of tests) SRL Limited gives the individual a clean chit to join the organization, on the basis of the General Physical Examination and the specific test panel requested for.
- Fit (with medical advice) (As per requested panel of tests) This indicates that although the candidate can be declared as FIT to join the job, minimal problems have been detected during the Pre- employment examination. Examples of conditions which could fall in this category could be cases of mild reversible medical abnormalities such as height weight disproportions, borderline raised Blood Pressure readings, mildly raised Blood sugar and Blood Lipid levels, Hematuria, etc. Most of these relate to sedentary lifestyles and come under the broad category of life style disorders. The idea is to caution an individual to bring about certain lifestyle changes as well as seek a Physician"
- consultation and counseling in order to bring back to normal the mildly deranged parameters. For all purposes the individual is FTT to join the job.

 Fitness on Hold (Temporary Unfit) (As per requested panel of tests) Candidate's reports are kept on hold when either the diagnostic tests or the physical findings reveal the presence of a medical condition which warrants further tests, counseling and/or specialist opinion, on the basis of which a candidate can either be placed into Fit, Fit (With Medical Advice), or Unfit category. Conditions which may fall into this category could be high blood pressure, abnormal ECG, heart murmurs, abnormal vision, grossly elevated blood sugars, etc.
- Unfit (As per requested panel of tests) An unfit report by SRL Limited clearly indicates that the individual is not suitable for the respective job profile e.g. total color blindness in color related jobs

Dr. Arpita Pasari, MD **Consultant Pathologist**





Page 5 Of 21







Female

PATIENT NAME: ALKA SHRIVASTAVA REF. DOCTOR: DR. ACROFEMI HEALTHCARE LTD (MEDIWHEEL)

CODE/NAME & ADDRESS: C000138355

ACROFEMI HEALTHCARE LTD (MEDIWHEEL)
F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030 8800465156 ACCESSION NO: 0290WD005364

PATIENT ID : ALKAF291177290

CHENT BATTENT ID:

AGE/SEX :45 Years

DRAWN :

RECEIVED : 22/04/2023 11:11:34 REPORTED : 24/04/2023 16:43:55

Test Report Status Final Results Biological Reference Interval Units

н	IAEMATOLOGY - CBC		
MEDI WHEEL FULL BODY HEALTH CHECKUP A	BOVE 40FEMALE		
BLOOD COUNTS,EDTA WHOLE BLOOD			
HEMOGLOBIN (HB) METHOD: SPECTROPHOTOMETRY	12.8	12.0 - 15.0	g/dL
RED BLOOD CELL (RBC) COUNT METHOD: ELECTRICAL IMPEDANCE	4.58	3.8 - 4.8	mil/μL
WHITE BLOOD CELL (WBC) COUNT METHOD: ELECTRICAL IMPEDANCE	9.50	4.0 - 10.0	thou/µL
PLATELET COUNT METHOD: ELECTRICAL IMPEDANCE	256	150 - 410	thou/µL
RBC AND PLATELET INDICES			
HEMATOCRIT (PCV) METHOD: CALCULATED	39.8	36 - 46	%
MEAN CORPUSCULAR VOLUME (MCV) METHOD: CALCULATED	87.0	83 - 101	fL
MEAN CORPUSCULAR HEMOGLOBIN (MCH) METHOD: CALCULATED	28.0	27.0 - 32.0	pg
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION (MCHC) METHOD: CALCULATED	32.2	31.5 - 34.5	g/dL
RED CELL DISTRIBUTION WIDTH (RDW) METHOD: CALCULATED	13.4	11.6 - 14.0	%
MENTZER INDEX	19.0		
MEAN PLATELET VOLUME (MPV)	9.6	6.8 - 10.9	fL
METHOD: CALCULATED			
WBC DIFFERENTIAL COUNT			
NEUTROPHILS METHOD: IMPEDANCE / MICROSCOPY	56	40 - 80	%
LYMPHOCYTES METHOD: IMPEDANCE / MICROSCOPY	34	20 - 40	%
MONOCYTES METHOD: IMPEDANCE / MICROSCOPY	04	2 - 10	%
EOSINOPHILS	06	1 - 6	%

Apita

Dr.Arpita Pasari, MD Consultant Pathologist





Page 6 Of 21

View Details

Minus Danasi





CODE/NAME & ADDRESS : C000138355 ACROFEMI HEALTHCARE LTD (MEDIWHEEL)

F-703, LADO SARAI, MEHRAULISOUTH WEST **DELHI**

NEW DELHI 110030 8800465156

ACCESSION NO: 0290WD005364

PATIENT ID : ALKAF291177290

CHIENT BATIENT ID:

AGE/SEX :45 Years Female

DRAWN

RECEIVED: 22/04/2023 11:11:34 REPORTED :24/04/2023 16:43:55

	:	<u> </u>	
Test Report Status <u>Final</u>	Results	Biological Reference Interval Units	
METHOD: IMPEDANCE / MICROSCOPY			
BASOPHILS METHOD: IMPEDANCE / MICROSCOPY	00	0 - 2	%
ABSOLUTE NEUTROPHIL COUNT METHOD: CALCULATED	5.32	2.0 - 7.0	thou/μL
ABSOLUTE LYMPHOCYTE COUNT METHOD: CALCULATED	3.23 High	1.0 - 3.0	thou/μL
ABSOLUTE MONOCYTE COUNT METHOD: CALCULATED	0.38	0.2 - 1.0	thou/μL
ABSOLUTE EOSINOPHIL COUNT	0.57 High	0.02 - 0.50	thou/µL

Interpretation(s)
BLOOD COUNTS,EDTA WHOLE BLOOD-The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading

RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13) from Beta thalassaemia trait

(<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for diagnosing a case of beta thalassaemia trait.

WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < 3.3, COVID-19 patients tend to show mild disease.

(Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients

A.-P. Yang, et al. International Immunopharmacology 84 (2020) 106504

This ratio element is a calculated parameter and out of NABL scope.

Dr. Arpita Pasari, MD **Consultant Pathologist**





Page 7 Of 21





CODE/NAME & ADDRESS : C000138355

ACROFEMI HEALTHCARE LTD (MEDIWHEEL)

F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030 8800465156 ACCESSION NO: 0290WD005364

PATIENT ID : ALKAF291177290

CHIENT BATTENT ID:

AGE/SEX :45 Years

DRAWN

ars Female

RECEIVED : 22/04/2023 11:11:34

REPORTED :24/04/2023 16:43:55

Test Report Status <u>Final</u> Results Biological Reference Interval Units

HAEMATOLOGY

MEDI WHEEL FULL BODY HEALTH CHECKUP ABOVE 40FEMALE

ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD

E.S.R 18 0-20 mm at 1 hr

METHOD: MODIFIED WESTERGREN

Interpretation(s)

ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD-TEST DESCRIPTION :-

Erythrocyte sedimentation rate (ESR), while below-rish beschir for a superior in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition.CRP is superior to ESR because it is more sensitive and reflects a more rapid change.

TEST INTERPRETATION

Increase in: Infections, Vasculities, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy,

Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias, Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis).

In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum.

Decreased in: Polycythermia vera, Sickle cell anemia

LIMITATIONS

False elevated ESR: Increased fibrinogen, Drugs(Vitamin A, Dextran etc), Hypercholesterolemia
False Decreased: Poikilocytosis, (SickleCells, spherocytes), Microcytosis, Low fibrinogen, Very high WBC counts, Drugs(Quinine,

salicylates)

REFERENCE :

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis,10th edition.

Dr.Arpita Pasari, MD

Page 8 Of 21





View Details

View Report



Consultant Pathologist





CODE/NAME & ADDRESS : C000138355 ACCESSION NO: 0290WD005364

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030 8800465156

PATIENT ID : ALKAF291177290

CHIENT BATTENT ID:

AGE/SEX :45 Years Female

DRAWN

RECEIVED: 22/04/2023 11:11:34 REPORTED :24/04/2023 16:43:55

Biological Reference Interval Test Report Status Results Units **Final**

IMMUNOHAEMATOLOGY

MEDI WHEEL FULL BODY HEALTH CHECKUP ABOVE 40FEMALE

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD

ABO GROUP TYPE O

METHOD: TUBE AGGLUTINATION

POSITIVE RH TYPE

METHOD: TUBE AGGLUTINATION

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same."

The test is performed by both forward as well as reverse grouping methods.

Dr. Arpita Pasari, MD **Consultant Pathologist**





Page 9 Of 21







CODE/NAME & ADDRESS : C000138355 ACCESSION NO: 0290WD005364 AGE/SEX

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) PATIENT ID F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030 8800465156

: ALKAF291177290

CHIENT BATIENT ID:

:45 Years

Female

DRAWN

RECEIVED: 22/04/2023 11:11:34 REPORTED :24/04/2023 16:43:55

Results **Biological Reference Interval Units Test Report Status Final**

BIOCHEMISTRY

MEDI WHEEL FULL BODY HEALTH CHECKUP ABOVE 40FEMALE

GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE **BLOOD**

HBA1C 5.6 Non-diabetic: < 5.7 %

Pre-diabetics: 5.7 - 6.4 Diabetics: > or = 6.5Therapeutic goals: < 7.0 Action suggested : > 8.0(ADA Guideline 2021)

METHOD: HPLC TECHNOLOGY

ESTIMATED AVERAGE GLUCOSE(EAG) 114.0 mg/dL < 116.0

GLUCOSE FASTING, FLUORIDE PLASMA

FBS (FASTING BLOOD SUGAR) 99 74 - 99 mg/dL

METHOD: HEXOKINASE

GLUCOSE, POST-PRANDIAL, PLASMA

PPBS(POST PRANDIAL BLOOD SUGAR) 161 High Normal: < 140, mg/dL

> Impaired Glucose Tolerance: 140-199 Diabetic > or = 200

METHOD: HEXOKINASE

LIPID PROFILE, SERUM

mg/dL CHOLESTEROL, TOTAL 198 Desirable: <200

BorderlineHigh: 200-239

High: > or = 240

METHOD: OXIDASE, ESTERASE, PEROXIDASE

TRIGLYCERIDES 212 High Desirable: < 150 mg/dL

Borderline High: 150 - 199

High: 200 - 499

Very High: > or = 500 METHOD: ENZYMATIC ASSAY

60 < 40 Low mg/dL HDL CHOLESTEROL

> or = 60 High

METHOD: DIRECT- NON IMMUNOLOGICAL

Dr. Arpita Pasari, MD **Consultant Pathologist**



Page 10 Of 21





PATIENT NAME: ALKA SHRIVASTAVA	REF. DOCTOR :	DR. ACROFEMI HEALTHCARE LTD (MEDIWHEEL)
CODE/NAME & ADDRESS: C000138355 ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	ACCESSION NO: 0290WD005364 PATIENT ID: ALKAF291177290 SHENT PATIENT ID:	AGE/SEX :45 Years Female DRAWN : RECEIVED :22/04/2023 11:11:34 REPORTED :24/04/2023 16:43:55

Test Report Status <u>Final</u>	Results	Biological Reference Interval Units
CHOLESTEROL LDL	96	Adult levels: mg/dL Optimal < 100 Near optimal/above optimal: 100-129 Borderline high: 130-159 High: 160-189 Very high: = 190
NON HDL CHOLESTEROL METHOD : CALCULATED	138 High	Desirable: Less than 130 mg/dL Above Desirable: 130 - 159 Borderline High: 160 - 189 High: 190 - 219 Very high: > or = 220
VERY LOW DENSITY LIPOPROTEIN METHOD: CALCULATED	42.4 High	< or = 30 mg/dL
CHOL/HDL RATIO	3.3	3.3 - 4.4
LDL/HDL RATIO	1.6	0.5 - 3.0 Desirable/Low Risk 3.1 - 6.0 Borderline/Moderate Risk >6.0 High Risk

Interpretation(s)

- 1) Cholesterol levels help assess the patient risk status and to follow the progress of patient under treatment to lower serum cholesterol concentrations.
- 2) Serum Triglyceride (TG) are a type of fat and a major source of energy for the body. Both quantity and composition of the diet impact on plasma triglyceride concentrations. Elevations in TG levels are the result of overproduction and impaired clearance. High TG are associated with increased risk for CAD (Coronary artery disease) in patients with other risk factors, such as low HDL-C, some patient groups with elevated apolipoprotein B concentrations, and patients with forms of LDL that may be particularly atherogenic.
- 3)HDL-C plays a crucial role in the initial step of reverse cholesterol transport, this considered to be the primary atheroprotective function of HDL
- 4) LDL -C plays a key role in causing and influencing the progression of atherosclerosis and, in particular, coronary sclerosis. The majority of cholesterol stored in atherosclerotic plaques originates from LDL, thus LDL-C value is the most powerful clinical predictor.
- 5)Non HDL cholesterol: Non-HDL-C measures the cholesterol content of all atherogenic lipoproteins, including LDL hence it is a better marker of risk in both primary and secondary prevention studies. Non-HDL-C also covers, to some extent, the excess ASCVD risk imparted by the sdLDL, which is significantly more atherogenic than the normal large buoyant particles, an elevated non-HDL-C indirectly suggests greater proportion of the small, dense variety of LDL particles

Serum lipid profile is measured for cardiovascular risk prediction. Lipid Association of India recommends LDL-C as primary target and Non

Dr.Arpita Pasari, MD Consultant Pathologist



Page 11 Of 21

lew Details

View Report





Female

PATIENT NAME: ALKA SHRIVASTAVA

REF. DOCTOR: DR. ACROFEMI HEALTHCARE LTD

(MEDIWHEEL)

CODE/NAME & ADDRESS : C000138355 ACCESSION NO : **0290WD005364** AGE/SEX : 45 Years
ACROFEMI HEALTHCARE LTD (MEDIWHEEL) PATIENT ID : ALKAF291177290 DRAWN :

F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI
NEW DELHI 110030

8800465156

RECEIVED : 22/04/2023 11:11:34
REPORTED : 24/04/2023 16:43:55

Test Report Status Final Results Biological Reference Interval Units

HDL-C as co-primary treatment target.

Risk Stratification for ASCVD (Atherosclerotic cardiovascular disease) by Lipid Association of India

Risk Category			
Extreme risk group	A.CAD with > 1 feature of high risk group		
		group or recurrent ACS (within 1 year) despite LDL-C	
	< or = 50 mg/dl or polyvascular disease		
Very High Risk	1. Established ASCVD 2. Diabetes with 2 1	major risk factors or evidence of end organ damage 3.	
	Familial Homozygous Hypercholesterolemi	a	
High Risk		abetes with 1 major risk factor or no evidence of end	
		DL >190 mg/dl 5. Extreme of a single risk factor. 6.	
	Coronary Artery Calcium - CAC >300 AU.	7. Lipoprotein a >/= 50mg/dl 8. Non stenotic carotid	
	plaque		
Moderate Risk	2 major ASCVD risk factors		
Low Risk	0-1 major ASCVD risk factors		
Major ASCVD (Ath	erosclerotic cardiovascular disease) Risk Fa	actors	
1. Age > or = 45 years in males and > or = 55 years in females 3. Current Cigarette smoking or tobacco use			
2. Family history of p	2. Family history of premature ASCVD 4. High blood pressure		
5. Low HDL			

Newer treatment goals and statin initiation thresholds based on the risk categories proposed by LAI in 2020.

Risk Group	Treatment Goals		Consider Drug Therapy	
	LDL-C (mg/dl)	Non-HDL (mg/dl)	LDL-C (mg/dl)	Non-HDL (mg/dl)
Extreme Risk Group	<50 (Optional goal	< 80 (Optional goal	>OR = 50	>OR = 80
Category A	< OR = 30)	$\langle OR = 60 \rangle$		
Extreme Risk Group	<OR = 30	<OR = 60	> 30	>60
Category B				
Very High Risk	<50	<80	>OR= 50	>OR= 80
High Risk	<70	<100	>OR= 70	>OR= 100
Moderate Risk	<100	<130	>OR= 100	>OR= 130
Low Risk	<100	<130	>OR= 130*	>OR= 160

^{*}After an adequate non-pharmacological intervention for at least 3 months.

References: Management of Dyslipidaemia for the Prevention of Stroke: Clinical Practice Recommendations from the Lipid Association of India. Current Vascular Pharmacology, 2022, 20, 134-155.

LIVER FUNCTION PROFILE, SERUM

BILIRUBIN, TOTAL 0.42 0.0 - 1.2 mg/dL

METHOD: JENDRASSIK AND GROFF

BILIRUBIN, DIRECT 0.16 0.0 - 0.2 mg/dL

 ${\tt METHOD:DIAZOTIZATION}$

Dr.Arpita Pasari, MD Consultant Pathologist





Page 12 Of 21

iew Details

View Report





CODE/NAME & ADDRESS: C000138355

ACROFEMI HEALTHCARE LTD (MEDIWHEEL)
F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030 8800465156 ACCESSION NO: **0290WD005364**PATIENT ID : ALKAF291177290

CHENT BATIENT ID:

AGE/SEX :45 Years Female

DRAWN :

RECEIVED : 22/04/2023 11:11:34 REPORTED :24/04/2023 16:43:55

Test Report Status <u>Final</u>	Results	Biological Reference	Interval Units	
BILIRUBIN, INDIRECT	0.26	0.00 - 1.00	mg/dL	
METHOD: CALCULATED				
TOTAL PROTEIN METHOD: BIURET	7.3	6.4 - 8.3	g/dL	
ALBUMIN METHOD: BROMOCRESOL GREEN	4.6	3.50 - 5.20	g/dL	
GLOBULIN METHOD: CALCULATED	2.7	2.0 - 4.1	g/dL	
ALBUMIN/GLOBULIN RATIO METHOD: CALCULATED	1.7	1.0 - 2.0	RATIO	
ASPARTATE AMINOTRANSFERASE(AST/SGOT) METHOD: UV WITH PSP	19	UPTO 32	U/L	
ALANINE AMINOTRANSFERASE (ALT/SGPT) METHOD: UV WITH PSP	26	UPTO 34	U/L	
ALKALINE PHOSPHATASE METHOD: PNPP	92	35 - 104	U/L	
GAMMA GLUTAMYL TRANSFERASE (GGT) METHOD: G-GLUTAMYL-CARBOXY-NITROANILIDE	17	5 - 36	U/L	
LACTATE DEHYDROGENASE METHOD: ENZYMATIC LACTATE - PYRUVATE(IFCC)	164	135 - 214	U/L	
BLOOD UREA NITROGEN (BUN), SERUM				
BLOOD UREA NITROGEN	7	6 - 20	mg/dL	
METHOD : UREASE KINETIC				
CREATININE, SERUM				
CREATININE	0.59	0.50 - 0.90	mg/dL	
METHOD: ALKALINE PICRATE KINETIC JAFFES				
BUN/CREAT RATIO				
BUN/CREAT RATIO METHOD: CALCULATED	11.86	5.0 - 15.0		
URIC ACID, SERUM				
URIC ACID METHOD: URICASE/CATALASE UV	3.4	2.6 - 6.0	mg/dL	
TOTAL PROTEIN, SERUM				
TOTAL PROTEIN METHOD: BIURET	7.3	6.4 - 8.3	g/dL	

Aprila

Dr.Arpita Pasari, MD Consultant Pathologist



Page 13 Of 21

View Details

\(\(\frac{1}{2} = \frac{1}{2} = \frac{1}{2}





CODE/NAME & ADDRESS: C000138355 ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030 8800465156

ACCESSION NO: 0290WD005364 PATIENT ID : ALKAF291177290

CPIENT BATIENT ID:

AGE/SEX :45 Years Female

DRAWN

RECEIVED: 22/04/2023 11:11:34 REPORTED :24/04/2023 16:43:55

Test Report Status <u>Final</u>	Results	Biological Reference	e Interval Units
ALBUMIN, SERUM			
ALBUMIN METHOD: BROMOCRESOL GREEN	4.6	3.5 - 5.2	g/dL
GLOBULIN			
GLOBULIN	2.7	2.0 - 4.1	g/dL
ELECTROLYTES (NA/K/CL), SERUM			
SODIUM, SERUM	140.5	136- 145	mmol/L
POTASSIUM, SERUM	4.58	3.50- 5.10	mmol/L
CHLORIDE, SERUM	102.7	98 - 107	mmol/L
Tuto-unustation(s)			

Interpretation(s)

Sodium	Potassium	Chloride
Decreased in:CCF, cirrhosis,	Decreased in: Low potassium	Decreased in: Vomiting, diarrhea, renal failure combined with salt
vomiting, diarrhea, excessive	intake, prolonged vomiting or diarrhea,	
sweating, salt-losing	RTA types I and II,	deprivation, over-treatment with
nephropathy, adrenal insufficiency,	hyperaldosteronism, Cushing's	diuretics, chronic respiratory acidosis
nephrotic syndrome, water	syndrome,osmotic diuresis (e.g.,	diabetic ketoacidosis, excessive
intoxication, SIADH. Drugs:	hyperglycemia), alkalosis, familial	sweating, SIADH, salt-losing
thiazides, diuretics, ACE inhibitors,	periodic paralysis,trauma	nephropathy, porphyria, expansion of
chlorpropamide,carbamazepine,anti	(transient).Drugs: Adrenergic agents,	extracellular fluid volume,
depressants (SSRI), antipsychotics.	diuretics.	adrenalinsufficiency,
		hyperaldosteronism, metabolic
		alkalosis. Drugs: chronic
		laxative,corticosteroids, diuretics.
Increased in: Dehydration	Increased in: Massive hemolysis,	Increased in: Renal failure, nephrotic
(excessivesweating, severe	severe tissue damage, rhabdomyolysis,	syndrome, RTA,dehydration,
vomiting or diarrhea),diabetes	acidosis, dehydration,renal failure,	overtreatment with
mellitus, diabetesinsipidus,	Addison's disease, RTA type IV,	saline,hyperparathyroidism, diabetes
hyperaldosteronism, inadequate	hyperkalemic familial periodic	insipidus, metabolic acidosis from
water intake. Drugs: steroids,	paralysis. Drugs: potassium salts,	diarrhea (Loss of HCO3-), respiratory
licorice,oral contraceptives.	potassium- sparing diuretics,NSAIDs,	alkalosis, hyperadre no corticism.
	beta-blockers, ACE inhibitors, high-	Drugs: acetazolamide, and rogens,
	dose trimethoprim-sulfamethoxazole.	hydrochlorothiazide, salicylates.
Interferences: Severe lipemia or	Interferences: Hemolysis of sample,	Interferences:Test is helpful in
hyperproteinemi, if sodium analysis	delayed separation of serum,	assessing normal and increased anion
involves a dilution step can cause	prolonged fist clenching during blood	gap metabolic acidosis and in
spurious results. The serum sodium	drawing, and prolonged tourniquet	distinguishing hypercalcemia due to
falls about 1.6 mEq/L for each 100	placement. Very high WBC/PLT counts	hyperparathyroidism (high serum
mg/dL increase in blood glucose.	may cause spurious. Plasma potassium	chloride) from that due to malignancy
-	levels are normal.	(Normal serum chloride)

Interpretation(s)

GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-**Used For**:

- 1. Evaluating the long-term control of blood glucose concentrations in diabetic patients.
- Diagnosing diabetes.
 Identifying patients at increased risk for diabetes (prediabetes).

Dr.Arpita Pasari, MD **Consultant Pathologist**





Page 14 Of 21





REF. DOCTOR: DR. ACROFEMI HEALTHCARE LTD **PATIENT NAME: ALKA SHRIVASTAVA** (MEDIWHEEL)

CODE/NAME & ADDRESS : C000138355 ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030 8800465156

ACCESSION NO: 0290WD005364

PATIENT ID : ALKAF291177290 CHIENT BATTENT ID:

DRAWN

AGE/SEX :45 Years Female

RECEIVED: 22/04/2023 11:11:34 REPORTED :24/04/2023 16:43:55

Test Report Status Results Biological Reference Interval Units **Final**

The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patients metabolic control has remained continuously within the target range.

1. eAG (Estimated average glucose) converts percentage HbA1c to md/dl, to compare blood glucose levels.

- eAG gives an evaluation of blood glucose levels for the last couple of months.
 eAG is calculated as eAG (mg/dl) = 28.7 * HbA1c 46.7

HbA1c Estimation can get affected due to :

- 1. Shortened Erythrocyte survival: Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss, hemolytic anemia) will falsely lower HbA1c test results. Fructosamine is recommended in these patients which indicates diabetes control over 15 days.
- 2. Vitamin C & E are reported to falsely lower test results. (possibly by inhibiting glycation of hemoglobin.
- 3. Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates addiction are reported to interfere with some assay methods, falsely increasing results.
- 4. Interference of hemoglobinopathies in HbA1c estimation is seen in
- a) Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c. b) Heterozygous state detected (D10 is corrected for HbS & HbC trait.)
- c) HbF > 25% on alternate paltform (Boronate affinity chromatography) is recommended for testing of HbA1c.Abnormal Hemoglobin electrophoresis (HPLC method) is GLUCOSE FASTING,FLUORIDE PLASMA-TEST DESCRIPTION

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and sothat no glucose is excreted in the

Increased in:Diabetes mellitus, Cushing's syndrome (10 – 15%), chronic pancreatitis (30%). Drugs:corticosteroids,phenytoin, estrogen, thiazides. **Decreased in**:Pancreatic islet cell disease with increased insulin,insulinoma,adrenocortical insufficiency,hypopituitarism,diffuse liver disease, malignancy(adrenocortical,stomach,fibrosarcoma),infant of a diabetic mother,enzyme deficiency diseases(e.g.galactosemia),Drugs-insulin,ethanol,propranolol

sulfonylureas, tolbutamide, and other oral hypoglycemic agents.

NOTE: While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within

individuals.Thus, glycosylated hemoglobin(HbA1c) levels are favored to monitor glycemic control.

High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment,Renal Glyosuria,Glycaemic

index & response to food consumed, Alimentary Hypoglycaemia, Increased insulin response & sensitivity etc.

GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc. Additional test HbA1c LIVER FUNCTION PROFILE, SERUM-

Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give yellow discoloration in jaundice. Elevated levels results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin wher there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors &Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin.

AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver, liver cancer, kidney failure, hemolytic anemia, pancreatitis, hemochromatosis. AST levels may also increase after a heart attack or strenuous activity. ALT test measures the amount of this enzyme in the blood. ALT is found mainly in the liver, but also in smaller amounts in the kidneys, heart, muscles, and pancreas. It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health AST levels increase during acute hepatitis, sometimes due to a viral infection, ischemia to the liver, chronic hepatitis.obstruction of bile ducts.cirrhosis

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Pagets disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia, Malnutrition, Protein deficiency, Wilsons disease.

GGT is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, biliary system and pancreas. Conditions that increase serum GGT are obstructive liver disease,high alcohol consumption and use of enzyme-inducing drugs etc.

Total Protein also known as total protein,is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and

globulin.Higher-than-normal levels may be due to:Chronic inflammation or infection,including HIV and hepatitis B or C,Multiple myeloma,Waldenstroms disease.Lower-than-normal levels may be due to: Agammaglobulinemia,Bleeding (hemorrhage),Burns,Glomerulonephritis,Liver disease, Malabsorption,Malnutrition,Nephrotic syndrome,Protein-losing enteropathy etc.

Albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular

permeability or decreased lymphatic clearance,malnutrition and wasting etc
BLOOD UREA NITROGEN (BUN), SERUM-**Causes of Increased** levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol, Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism)

Causes of decreased level include Liver disease, SIADH.

Dr. Arpita Pasari, MD Consultant Pathologist



Page 15 Of 21

View Report



Tel: 0731 2490008

Agilus Diagnostics Ltd (Formerly SRL Ltd) Gate No 2, Residency Area, Opp. St. Raphaels School, Indore, 452001 Madhya Pradesh, India

Patient Ref. No. 7750000029821



CODE/NAME & ADDRESS : C000138355 ACROFEMI HEALTHCARE LTD (MEDIWHEEL)

F-703, LADO SARAI, MEHRAULISOUTH WEST **DELHI**

NEW DELHI 110030 8800465156

ACCESSION NO: 0290WD005364 PATIENT ID : ALKAF291177290

CHIENT BATIENT ID:

:45 Years AGE/SEX

Female

DRAWN

RECEIVED: 22/04/2023 11:11:34 REPORTED :24/04/2023 16:43:55

Results **Biological Reference Interval Units Test Report Status Final**

CREATININE, SERUM-Higher than normal level may be due to:

CREATININE, SERUM-Higher than normal level may be due to:

Blockage in the urinary tract, Kidney problems, such as kidney damage or failure, infection, or reduced blood flow, Loss of body fluid (dehydration), Muscle problems, such as breakdown of muscle fibers, Problems during pregnancy, such as seizures (eclampsia)), or high blood pressure caused by pregnancy (preeclampsia)

Lower than normal level may be due to: Myasthenia Gravis, Muscuophy

URIC ACID, SERUM-Causes of Increased levels:-Dietary(High Protein Intake,Prolonged Fasting,Rapid weight loss),Gout,Lesch nyhan syndrome,Type 2 DM,Metabolic syndrome Causes of decreased levels-Low Zinc intake,OCP,Multiple Sclerosis

TOTAL PROTEIN, SERUM-is a biochemical test for measuring the total amount of protein in serum.Protein in the plasma is made up of albumin and globulin.

Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitics B or C, Multiple myeloma,Waldenstroms disease.

Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc. ALBUMIN, SERUM-

Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. **Low blood albumin levels (hypoalbuminemia) can be caused by:** Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance,malnutrition and wasting etc.

Dr. Arpita Pasari, MD **Consultant Pathologist**





Page 16 Of 21

PERFORMED AT:





CHIENT BATIENT ID:

PATIENT ID

CODE/NAME & ADDRESS : C000138355 ACROFEMI HEALTHCARE LTD (MEDIWHEEL)

F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030 8800465156

ACCESSION NO: 0290WD005364

: ALKAF291177290

DRAWN

Female

AGE/SEX :45 Years

RECEIVED: 22/04/2023 11:11:34

REPORTED :24/04/2023 16:43:55

Results Biological Reference Interval Units **Test Report Status Final**

CLINICAL PATH - URINALYSIS

MEDI WHEEL FULL BODY HEALTH CHECKUP ABOVE 40FEMALE

PHYSICAL EXAMINATION, URINE

COLOR PALE YELLOW **APPEARANCE CLEAR**

CHEMICAL EXAMINATION, URINE

PH	5.0	4.7 - 7.5
SPECIFIC GRAVITY	1.015	1.003 - 1.035
PROTEIN	NOT DETECTED	NOT DETECTED
GLUCOSE	NOT DETECTED	NOT DETECTED
KETONES	NOT DETECTED	NOT DETECTED
BLOOD	NOT DETECTED	NOT DETECTED
BILIRUBIN	NOT DETECTED	NOT DETECTED
UROBILINOGEN	NORMAL	NORMAL
NITRITE	NOT DETECTED	NOT DETECTED
LEUKOCYTE ESTERASE	NOT DETECTED	NOT DETECTED
MICROSCOPIC EXAMINATION LIRINE		

MICROSCOPIC EXAMINATION, URINE

RED BLOOD CELLS	NOT DETECTED	NOT DETECTED	/HPF
PUS CELL (WBC'S)	2-3	0-5	/HPF
EPITHELIAL CELLS	3-5	0-5	/HPF

CASTS NOT DETECTED **CRYSTALS** NOT DETECTED

BACTERIA NOT DETECTED NOT DETECTED YEAST **NOT DETECTED** NOT DETECTED

REMARKS Please note that all the urinary findings are confirmed manually as well.

Interpretation(s)

The following table describes the probable conditions, in which the analytes are present in urine

Presence of	Conditions	
Proteins	Inflammation or immune illnesses	

Dr. Arpita Pasari, MD **Consultant Pathologist**





Page 17 Of 21





CODE/NAME & ADDRESS: C000138355 ACROFEMI HEALTHCARE LTD (MEDIWHEEL) PATIENT ID

F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI

NEW DELHI 110030 8800465156

ACCESSION NO: 0290WD005364

: ALKAF291177290

CPIENT BATIENT ID:

AGE/SEX :45 Years Female DRAWN

RECEIVED: 22/04/2023 11:11:34 REPORTED :24/04/2023 16:43:55

Test Report Status Results **Biological Reference Interval Units Final**

Pus (White Blood Cells)	Blood Cells) Urinary tract infection, urinary tract or kidney stone, tumors or any kind			
	of kidney impairment			
Glucose	Diabetes or kidney disease			
Ketones	Diabetic ketoacidosis (DKA), starvation or thirst			
Urobilinogen	Liver disease such as hepatitis or cirrhosis			
Blood	Renal or genital disorders/trauma			
Bilirubin	Liver disease			
Erythrocytes	Urological diseases (e.g. kidney and bladder cancer, urolithiasis), urinary			
	tract infection and glomerular diseases			
Leukocytes	Urinary tract infection, glomerulonephritis, interstitial nephritis either			
	acute or chronic, polycystic kidney disease, urolithiasis, contamination by			
	genital secretions			
Epithelial cells	Urolithiasis, bladder carcinoma or hydronephrosis, ureteric stents or			
	bladder catheters for prolonged periods of time			
Granular Casts	Low intratubular pH, high urine osmolality and sodium concentration,			
	interaction with Bence-Jones protein			
Hyaline casts	Physical stress, fever, dehydration, acute congestive heart failure, renal			
	diseases			
Calcium oxalate	Metabolic stone disease, primary or secondary hyperoxaluria, intravenous			
	infusion of large doses of vitamin C, the use of vasodilator naftidrofuryl			
	oxalate or the gastrointestinal lipase inhibitor orlistat, ingestion of			
	ethylene glycol or of star fruit (Averrhoa carambola) or its juice			
Uric acid	arthritis			
Bacteria	Urinary infectionwhen present in significant numbers & with pus cells.			
Trichomonas vaginalis Vaginitis, cervicitis or salpingitis				

Dr.Arpita Pasari, MD **Consultant Pathologist**





Page 18 Of 21





REF. DOCTOR: DR. ACROFEMI HEALTHCARE LTD **PATIENT NAME: ALKA SHRIVASTAVA** (MEDIWHEEL)

CODE/NAME & ADDRESS : C000138355 ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030 8800465156

ACCESSION NO: 0290WD005364

PATIENT ID : ALKAF291177290 CHIENT BATTENT ID:

AGE/SEX :45 Years

Female DRAWN

RECEIVED: 22/04/2023 11:11:34 REPORTED :24/04/2023 16:43:55

Biological Reference Interval Units Test Report Status Results **Final**

SPECIALISED CHEMISTRY - HORMONE

MEDI WHEEL FULL BODY HEALTH CHECKUP ABOVE 40FEMALE

THYROID PANEL, SERUM

T3 142.00 Non-Pregnant Women ng/dL

> 80.0 - 200.0 Pregnant Women

1st Trimester: 105.0 - 230.0 2nd Trimester: 129.0 - 262.0

3rd Trimester: 135.0 - 262.0

METHOD: CHEMILUMINESCENCE TECHNOLOGY

μg/dL T4 8.54 Non-Pregnant Women

5.10 - 14.10 Pregnant Women

1st Trimester: 7.33 - 14.80 2nd Trimester: 7.93 - 16.10 3rd Trimester: 6.95 - 15.70

METHOD: CHEMILUMINESCENCE TECHNOLOGY

2.260 TSH (ULTRASENSITIVE) Non Pregnant Women μIU/mL

0.27 - 4.20Pregnant Women

1st Trimester: 0.33 - 4.59 2nd Trimester: 0.35 - 4.10 3rd Trimester: 0.21 - 3.15

METHOD: CHEMILUMINESCENCE TECHNOLOGY

Interpretation(s)

Triiodothyronine T3, Thyroxine T4, and Thyroid Stimulating Hormone TSH are thyroid hormones which affect almost every physiological process in the body, including growth, development, metabolism, body temperature, and heart rate.

Production of T3 and its prohormone thyroxine (T4) is activated by thyroid-stimulating hormone (TSH), which is released from the pituitary gland. Elevated concentrations of T3, and T4 in the blood inhibit the production of TSH.

Excessive secretion of thyroxine in the body is hyperthyroidism, and deficient secretion is called hypothyroidism.

In primary hypothyroidism, TSH levels are significantly elevated, while in secondary and tertiary hypothyroidism, TSH levels are low, Below mentioned are the guidelines for Pregnancy related reference ranges for Total T4, TSH & Total T3. Measurement of the serum TT3 level is a more sensitive test for the diagnosis of hyperthyroidism, and measurement of TT4 is more useful in the diagnosis of hypothyroidism. Most of the thyroid hormone in blood is bound to transport proteins. Only a very small fraction of the circulating hormone is free and biologically active. It is advisable to detect Free T3, Free T4 along with TSH, instead of testing for albumin bound Total T3, Total T4.

Sr. No. **TSH** Total T4 | FT4 **Total T3 Possible Conditions**

Dr. Arpita Pasari, MD **Consultant Pathologist**





Page 19 Of 21

Patient Ref. No.



Female

PATIENT NAME: ALKA SHRIVASTAVA

REF. DOCTOR: DR. ACROFEMI HEALTHCARE LTD

(MEDIWHEEL)

CODE/NAME & ADDRESS: C000138355

ACROFEMI HEALTHCARE LTD (MEDIWHEEL)
F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030 8800465156 ACCESSION NO: 0290WD005364

| |PATIENT ID : ALKAF291177290

CHIENT BATTENT ID:

AGE/SEX : 45 Years

DRAWN :

RECEIVED : 22/04/2023 11:11:34

REPORTED :24/04/2023 16:43:55

Test Report Status <u>Final</u> Results Biological Reference Interval Units

1	High	Low	Low	Low	(1) Primary Hypothyroidism (2) Chronic autoimmune Thyroiditis (3)
					Post Thyroidectomy (4) Post Radio-Iodine treatment
2	High	Normal	Normal	Normal	(1)Subclinical Hypothyroidism (2) Patient with insufficient thyroid hormone replacement therapy (3) In cases of Autoimmune/Hashimoto thyroiditis (4). Isolated increase in TSH levels can be due to Subclinical inflammation, drugs like amphetamines, Iodine containing drug and dopamine antagonist e.g. domperidone and other physiological reasons.
3	Normal/Low	Low	Low	Low	(1) Secondary and Tertiary Hypothyroidism
4	Low	High	High	High	(1) Primary Hyperthyroidism (Graves Disease) (2) Multinodular Goitre (3) Toxic Nodular Goitre (4) Thyroiditis (5) Over treatment of thyroid hormone (6) Drug effect e.g. Glucocorticoids, dopamine, T4 replacement therapy (7) First trimester of Pregnancy
5	Low	Normal	Normal	Normal	(1) Subclinical Hyperthyroidism
6	High	High	High	High	(1) TSH secreting pituitary adenoma (2) TRH secreting tumor
7	Low	Low	Low	Low	(1) Central Hypothyroidism (2) Euthyroid sick syndrome (3) Recent treatment for Hyperthyroidism
8	Normal/Low	Normal	Normal	High	(1) T3 thyrotoxicosis (2) Non-Thyroidal illness
9	Low	High	High	Normal	(1) T4 Ingestion (2) Thyroiditis (3) Interfering Anti TPO antibodies

REF: 1. TIETZ Fundamentals of Clinical chemistry 2.Guidlines of the American Thyroid association during pregnancy and Postpartum, 2011. **NOTE: It is advisable to detect Free T3,FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.**TSH is not affected by variation in thyroid - binding protein. TSH has a diurnal rhythm, with peaks at 2:00 - 4:00 a.m. And troughs at 5:00 - 6:00 p.m. With ultradian variations.

End Of Report
Please visit www.srlworld.com for related Test Information for this accession

Dr.Arpita Pasari, M

Dr.Arpita Pasari, MD Consultant Pathologist





Page 20 Of 21

iew Details





Female

PATIENT NAME: ALKA SHRIVASTAVA

REF. DOCTOR: DR. ACROFEMI HEALTHCARE LTD

(MEDIWHEEL)

CODE/NAME & ADDRESS : C000138355

ACROFEMI HEALTHCARE LTD (MEDIWHEEL)
F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030 8800465156 ACCESSION NO: **0290WD005364**PATIENT ID : ALKAF291177290

ABIENT BATTENT ID:

AGE/SEX : 45 Years

DRAWN :

RECEIVED : 22/04/2023 11:11:34 REPORTED : 24/04/2023 16:43:55

Test Report Status Final Results Biological Reference Interval Units

CONDITIONS OF LABORATORY TESTING & REPORTING

- 1. It is presumed that the test sample belongs to the patient named or identified in the test requisition form.
- 2. All tests are performed and reported as per the turnaround time stated in the AGILUS Directory of Services.
- 3. Result delays could occur due to unforeseen circumstances such as non-availability of kits / equipment breakdown / natural calamities / technical downtime or any other unforeseen event.
- 4. A requested test might not be performed if:
 - i. Specimen received is insufficient or inappropriate
 - ii. Specimen quality is unsatisfactory
 - iii. Incorrect specimen type
 - iv. Discrepancy between identification on specimen container label and test requisition form

- 5. AGILUS Diagnostics confirms that all tests have been performed or assayed with highest quality standards, clinical safety & technical integrity.
- 6. Laboratory results should not be interpreted in isolation; it must be correlated with clinical information and be interpreted by registered medical practitioners only to determine final diagnosis.
- 7. Test results may vary based on time of collection, physiological condition of the patient, current medication or nutritional and dietary changes. Please consult your doctor or call us for any clarification.
- 8. Test results cannot be used for Medico legal purposes.
- 9. In case of queries please call customer care (91115 91115) within 48 hours of the report.

Agilus Diagnostics Limited

Fortis Hospital, Sector 62, Phase VIII, Mohali 160062

Pepita

Dr.Arpita Pasari, MD Consultant Pathologist





Page 21 Of 21

liew Details

View Report



